SPARTA is a robust antibody discovery methodology. It combines an in vitro screening step of a naïve human antibody library against tumor targets, with in vivo selections based on tumor-homing capabilities of a pre-enriched antibody pool. This unique approach overcomes several rate-limiting challenges for rapid translation into clinical applications.
The SPARTA approach accelerates the development of antibody-based drugs for personalized medicine.
Our pipeline is applicable for any target and will address all core aspects of antibody generation including: 1) selection, sequencing, and expression, 2) characterization and 3) in-vivo testing.